# Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
Canonical URL: https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-bofa-securities-2026-health-care-conference
Ticker: PGNY
Company: Progyny
Source: Progyny
Published: 2026-05-11 14:57 EST
Original Source URL: https://investors.progyny.com
## Summary

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that Progyny’s Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the

## Article Body
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that Progyny’s Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the
## Recent Company News
- 2026-05-28 13:04 EST — [New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System](https://biopharmsignal.com/news/PGNY/new-progyny-study-shows-growing-demand-for-human-guidance-in-an-increasingly-digital-healthcare-system) — Source: Progyny
- 2026-05-26 12:00 EST — [Progyny, Inc. Announces Share Repurchase Program](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-share-repurchase-program) — Source: Progyny
- 2026-05-11 14:57 EST — [Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/PGNY/progyny-inc-to-present-at-bofa-securities-2026-health-care-conference) — Source: Progyny
- 2026-05-07 20:01 EST — [Progyny, Inc. Announces First Quarter 2026 Results](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-first-quarter-2026-results) — Source: Progyny
- 2026-04-23 17:56 EST — [Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report](https://biopharmsignal.com/news/PGNY/progyny-inc-announces-details-for-its-first-quarter-2026-results-report) — Source: Progyny
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)